Biotech stocks are regaining
some lost momentum after Wednesday's Trump-inspired
selloff that took a toll on the sentiment on pharma sector.
The weakness was so stark
that it made CNBC's Brian Sullivan tweet that biotechs/healthcare was the only sector to have been left out of what seemed to be a
market-wide rally on Wednesday.
But, the month of January offers some catalysts for biotech investors to make some money from the sector. There are certain
biopharma stocks investors should keep on their radar for the remainder of this month.
Following is a look at several biotech catalysts this month, according to BioPharmCatalyst.
Upcoming Catalysts
The FDA is slated for a response on the NDA of baricitinib,
Incyte Corporation (NASDAQ:
INCY)’s rheumatoid arthritis drug candidate, by January 19,
2017. Baricitinib was submitted in an NDA in January 2016. The drug is being developed in partnership with
Eli Lilly and
Co (NYSE:
LLY). In December, European Medicines
Agency's Committee for Medicinal Products for Human Use has issued a positive opinion on baricitinib.
FibroGen Inc
(NASDAQ:
FGEN) will release an abstract of its Phase 2 study
of its pancreatic cancer drug, FG-3019, on January 17. The data is due at ASCO GI on January 20. The PDUFA date for
Synergy
Pharmaceuticals Inc (NASDAQ:
SGYP)’ plecanatide for
the treatment of chronic idiopathic constipation is January 29.
Neurocrine Biosciences, Inc. (NASDAQ:
NBIX) is expected to announce Phase 2 data of its Tourette syndrome
treatment, INGREZZA, in the week of January 16.
Heron Therapeutics Inc (NASDAQ:
HRTX) is set to file its NDA for HTX-019 for prevention of chemotherapy-induced
nausea and vomiting in January. In January,
Tenax Therapeutics Inc (NASDAQ:
TENX) is expected to release Phase 3 top-line data for levosimendan, which is being
studied for reduction of the incidence of low cardiac output syndrome during cardiac surgery.
Dimension Therapeutics
Inc (NASDAQ:
DMTX) is set to announce Phase 1/2
initial data for hemophilia B treatment, DTX101, this month.
At last check, shares of iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) rose 1.19 percent to $282.25.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.